Johnson & Johnson FDA Approval
Yesterday, September 11, 2024,  Johnson & Johnson (JNJ) announced that the FDA has approved TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC) - a chronic disease of the large intestine in which the lining of the colon becomes inflamed. 
About Ulcerative Colitis
Ulcerative colitis is a form of inflammatory bowel . . .